Consensus subtypes of hepatocellular carcinoma associated with clinical outcomes and genomic phenotypes

Background and Aims Although many studies revealed transcriptomic subtypes of HCC, concordance of the subtypes are not fully examined. We aim to examine a consensus of transcriptomic subtypes and correlate them with clinical outcomes. Approach and Results By integrating 16 previously established gen...

Full description

Saved in:
Bibliographic Details
Published inHepatology (Baltimore, Md.) Vol. 76; no. 6; pp. 1634 - 1648
Main Authors Lee, Sung Hwan, Yim, Sun Young, Jeong, Yun Seong, Li, Qi‐Xiang, Kang, Sang‐Hee, Sohn, Bo Hwa, Kumar, Shwetha V., Shin, Ji‐Hyun, Choi, You Rhee, Shim, Jae‐Jun, Kim, Hayeon, Kim, Ji Hoon, Kim, Shin, Guo, Sheng, Johnson, Randy L., Kaseb, Ahmed, Kang, Koo Jeong, Chun, Yun Shin, Jang, Hee Jin, Lee, Byoung Gill, Woo, Hyun Goo, Ha, Min Jin, Akbani, Rehan, Roberts, Lewis R., Wheeler, David A., Lee, Ju‐Seog
Format Journal Article
LanguageEnglish
Published United States Wiley Subscription Services, Inc 01.12.2022
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Background and Aims Although many studies revealed transcriptomic subtypes of HCC, concordance of the subtypes are not fully examined. We aim to examine a consensus of transcriptomic subtypes and correlate them with clinical outcomes. Approach and Results By integrating 16 previously established genomic signatures for HCC subtypes, we identified five clinically and molecularly distinct consensus subtypes. STM (STeM) is characterized by high stem cell features, vascular invasion, and poor prognosis. CIN (Chromosomal INstability) has moderate stem cell features, but high genomic instability and low immune activity. IMH (IMmune High) is characterized by high immune activity. BCM (Beta‐Catenin with high Male predominance) is characterized by prominent β‐catenin activation, low miRNA expression, hypomethylation, and high sensitivity to sorafenib. DLP (Differentiated and Low Proliferation) is differentiated with high hepatocyte nuclear factor 4A activity. We also developed and validated a robust predictor of consensus subtype with 100 genes and demonstrated that five subtypes were well conserved in patient‐derived xenograft models and cell lines. By analyzing serum proteomic data from the same patients, we further identified potential serum biomarkers that can stratify patients into subtypes. Conclusions Five HCC subtypes are correlated with genomic phenotypes and clinical outcomes and highly conserved in preclinical models, providing a framework for selecting the most appropriate models for preclinical studies.
Bibliography:Funding information
Supported, in part, by National Cancer Institute grant R01‐CA237327, P50‐CA217674, the Duncan Cancer Prevention Research Seed Funding Program at MD Anderson Cancer Center (2016 cycle), the MD Anderson Sister Institute Network Fund (2016 and 2019 cycles), and the National Institutes of Health through MD Anderson’s Cancer Center Support Grant P30 CA016672. S.H.L. was supported by the Severance Research Initiative (SRI) project in Yonsei University College of Medicine. Acquisition of blood samples was supported by grant CA165076, the Mayo Clinic Cancer Center (P30‐CA015083), and Mayo Clinic Hepatobiliary SPORE (P50‐CA210964) to L.R.R.
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
These authors contributed equally.
Authors’ contributions
J-SL conceived and designed the study. SHL, SYY, SHK, BHS, JHS, SG, Q-XL, and J-SL collected, analyzed, and interpreted the data and wrote the manuscript. SHL, SHK, YRC, and J-SL performed the statistical analysis. KJK, JK, and LRR provided study material and clinical data. YSJ, JHS, HJJ, HK, BGL, HGW and SK analyzed the data. JJS, JK, RLJ, AK, YSC, and DAW analyzed and interpreted the data. All authors contributed to the final approval of the manuscript.
ISSN:0270-9139
1527-3350
DOI:10.1002/hep.32490